Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMLK2QH)

• Drug Name: Nateglinide Drug Info
• Synonyms: Fastic; IPCCPA; Senaglinide; Starlix; Starsis; Trazec; Nateglinide [INN]; Novartis brand of nateglinide; DJN 608; A-4166; AY-4166; DJN-608; Nate-glinide; Starlix (TN); YM-026; SDZ-DJN-608; N-((4-isopropylcyclohexyl)carbonyl)phenylalanine; Nateglinide, (D-Phe)-isomer; Nateglinide, (cis,D-Phe)-isomer; N-{[4-(propan-2-yl)cyclohexyl]carbonyl}phenylalanine; N-{[trans-4-(propan-2-yl)cyclohexyl]carbonyl}-D-phenylalanine; (2R)-3-phenyl-2-[(4-propan-2-ylcyclohexanecarbonyl)amino]propanoic acid; 3-phenyl-2-[(4-propan-2-ylcyclohexanecarbonyl)amino]propanoic acid

Indication

Disease Entry	ICD 11	Status	REF
Diabetic complication	5A2Y	Approved	[1]

• Therapeutic Class: Hypoglycemic Agents
• Cross-matching ID:
  PubChem CID: 5311309
  ChEBI ID: CHEBI:31897
  CAS Number: CAS 105816-04-4
  TTD Drug ID: DMLK2QH
  VARIDT Drug ID: DR00407
  INTEDE Drug ID: DR1132
  ACDINA Drug ID: D00458

Molecule-Related Drug Atlas

Drug(s) Targeting Potassium channel unspecific (KC)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Amiodarone	DMUTEX3	Tachyarrhythmias	BC71	Approved	[2]
Dronedarone	DMA8FS5	Angina pectoris	BA40	Approved	[12]
Dofetilide	DMPN1TW	Sinus rhythm disorder	BC9Y	Approved	[2]
Amifampridine	DMK08L3	LambertEaton myasthenic syndrome	8C62	Approved	[13]
Minoxidil	DMA2Z4F	Alopecia	ED70	Approved	[2]
Pinacidil	DMRADYL	High blood pressure	BA00	Approved	[2]
Dalfampridine	DMM0PDO	Multiple sclerosis	8A40	Approved	[14]
Ibutilide	DMKXY2R	Atrial fibrillation	BC81.3	Approved	[2]
Diazoxide	DML1538	Congenital hyperinsulinism	5A4Y	Approved	[2]
Azimilide	DMUIBV8	Atrial fibrillation	BC81.3	Phase 3	[15]

Drug(s) Transported By Organic anion transporting polypeptide 1B1 (SLCO1B1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[16]
Dinoprostone	DMTYOPD	Medical abortion	JA00.1Z	Approved	[17]
Imatinib	DM7RJXL	Acute lymphoblastic leukaemia	2A85	Approved	[18]
Etoposide	DMNH3PG	Acute myelogenous leukaemia	2A41	Approved	[19]
Sorafenib	DMS8IFC	Adenocarcinoma	2D40	Approved	[18]
Pravastatin	DM6A0X7	Adult acute monocytic leukemia		Approved	[20]
Mycophenolate mofetil	DMPQAGE	Hepatosplenic T-cell lymphoma		Approved	[21]
Atorvastatin	DMF28YC	Acute coronary syndrome	BA41	Approved	[22]
Cerivastatin	DMXCM7H	Hyperlipidaemia	5C80	Approved	[5]
PITAVASTATIN CALCIUM	DM1UJO0	Dyslipidemia	5C80-5C81	Approved	[20]

Drug(s) Transported By Organic anion transporting polypeptide 1B3 (SLCO1B3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[23]
Imatinib	DM7RJXL	Acute lymphoblastic leukaemia	2A85	Approved	[18]
Etoposide	DMNH3PG	Acute myelogenous leukaemia	2A41	Approved	[24]
Diclofenac	DMPIHLS	Chronic renal failure	GB61.Z	Approved	[25]
Sorafenib	DMS8IFC	Adenocarcinoma	2D40	Approved	[18]
Pravastatin	DM6A0X7	Adult acute monocytic leukemia		Approved	[26]
Mycophenolate mofetil	DMPQAGE	Hepatosplenic T-cell lymphoma		Approved	[21]
Atorvastatin	DMF28YC	Acute coronary syndrome	BA41	Approved	[5]
Erythromycin	DM4K7GQ	Acne vulgaris	ED80	Approved	[27]
Cerivastatin	DMXCM7H	Hyperlipidaemia	5C80	Approved	[5]

Drug(s) Transported By Monocarboxylate transporter 6 (SLC16A5)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Bumetanide	DMRV7H0	Congestive heart failure	BD10	Approved	[3]
Probenecid	DMMFWOJ	Acute gonococcal cervicitis		Approved	[3]

Drug(s) Metabolized By Cytochrome P450 3A4 (CYP3A4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[28]
Progesterone	DMUY35B	Amenorrhea	GA20.0	Approved	[29]
Tamoxifen	DMLB0EZ	Breast cancer	2C60-2C65	Approved	[30]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[31]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[32]
Imatinib	DM7RJXL	Acute lymphoblastic leukaemia	2A85	Approved	[33]
Etoposide	DMNH3PG	Acute myelogenous leukaemia	2A41	Approved	[34]
Zidovudine	DM4KI7O	Human immunodeficiency virus infection	1C62	Approved	[35]
Prasterone	DM67VKL	Chronic obstructive pulmonary disease	CA22	Approved	[29]
Verapamil	DMA7PEW	Angina pectoris	BA40	Approved	[9]

Drug(s) Metabolized By Cytochrome P450 2D6 (CYP2D6)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[36]
Progesterone	DMUY35B	Amenorrhea	GA20.0	Approved	[37]
Tamoxifen	DMLB0EZ	Breast cancer	2C60-2C65	Approved	[38]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[32]
Imatinib	DM7RJXL	Acute lymphoblastic leukaemia	2A85	Approved	[9]
Quinine	DMSWYF5	Malaria	1F40-1F45	Approved	[39]
Propofol	DMB4OLE	Anaesthesia	9A78.6	Approved	[40]
Dopamine	DMPGUCF	Acromegaly	5A60.0	Approved	[41]
Nicotine	DMWX5CO	Lung cancer	2C25.0	Approved	[42]
Propranolol	DM79NTF	Angina pectoris	BA40	Approved	[43]

Drug(s) Metabolized By Cytochrome P450 3A5 (CYP3A5)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[44]
Progesterone	DMUY35B	Amenorrhea	GA20.0	Approved	[45]
Tamoxifen	DMLB0EZ	Breast cancer	2C60-2C65	Approved	[46]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[8]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[47]
Sulfasalazine	DMICA9H	Irritable bowel syndrome	DD91.0	Approved	[48]
Imatinib	DM7RJXL	Acute lymphoblastic leukaemia	2A85	Approved	[49]
Etoposide	DMNH3PG	Acute myelogenous leukaemia	2A41	Approved	[50]
Verapamil	DMA7PEW	Angina pectoris	BA40	Approved	[51]
Sorafenib	DMS8IFC	Adenocarcinoma	2D40	Approved	[8]

Drug(s) Metabolized By Cytochrome P450 3A7 (CYP3A7)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Progesterone	DMUY35B	Amenorrhea	GA20.0	Approved	[52]
Tamoxifen	DMLB0EZ	Breast cancer	2C60-2C65	Approved	[8]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[8]
Imatinib	DM7RJXL	Acute lymphoblastic leukaemia	2A85	Approved	[8]
Prasterone	DM67VKL	Chronic obstructive pulmonary disease	CA22	Approved	[53]
Verapamil	DMA7PEW	Angina pectoris	BA40	Approved	[54]
Sorafenib	DMS8IFC	Adenocarcinoma	2D40	Approved	[8]
Quinine	DMSWYF5	Malaria	1F40-1F45	Approved	[8]
Irinotecan	DMP6SC2	Adenocarcinoma	2D40	Approved	[8]
Metronidazole	DMTIVEN	Abscess		Approved	[55]

Drug(s) Metabolized By Cytochrome P450 2C9 (CYP2C9)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Progesterone	DMUY35B	Amenorrhea	GA20.0	Approved	[56]
Tamoxifen	DMLB0EZ	Breast cancer	2C60-2C65	Approved	[57]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[58]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[53]
Imatinib	DM7RJXL	Acute lymphoblastic leukaemia	2A85	Approved	[59]
Zidovudine	DM4KI7O	Human immunodeficiency virus infection	1C62	Approved	[53]
Verapamil	DMA7PEW	Angina pectoris	BA40	Approved	[60]
Diclofenac	DMPIHLS	Chronic renal failure	GB61.Z	Approved	[61]
Estrone	DM5T6US	Acne vulgaris	ED80	Approved	[62]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[63]

Drug(s) Metabolized By UDP-glucuronosyltransferase 1A9 (UGT1A9)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[64]
Diclofenac	DMPIHLS	Chronic renal failure	GB61.Z	Approved	[65]
Sorafenib	DMS8IFC	Adenocarcinoma	2D40	Approved	[66]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[9]
Mycophenolate mofetil	DMPQAGE	Hepatosplenic T-cell lymphoma		Approved	[67]
Propofol	DMB4OLE	Anaesthesia	9A78.6	Approved	[9]
Ibuprofen	DM8VCBE	Dysmenorrhea	GA34.3	Approved	[9]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[68]
Haloperidol	DM96SE0	Delirium		Approved	[9]
Naproxen	DMZ5RGV	Bursitis		Approved	[69]

Drug(s) Metabolized By Prostaglandin G/H synthase 1 (COX-1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Imatinib	DM7RJXL	Acute lymphoblastic leukaemia	2A85	Approved	[9]
Etoposide	DMNH3PG	Acute myelogenous leukaemia	2A41	Approved	[70]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[9]
Diazepam	DM08E9O	Alcohol withdrawal		Approved	[9]
Dapsone	DM4LT8A	Acne vulgaris	ED80	Approved	[9]
Ifosfamide	DMCT3I8	Adult central nervous system germ cell tumor		Approved	[9]
Thalidomide	DM70BU5	Adult T-cell leukemia/lymphoma		Approved	[9]
Ketobemidone	DMM3L6Z	Pain	MG30-MG3Z	Approved	[9]
Irbesartan	DMTP1DC	Diabetic kidney disease	GB61.Z	Approved	[9]
Terbinafine	DMI6HUW	Fungal infection	1F29-1F2F	Approved	[9]

Drug(s) Affected By Insulin (INS)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tolbutamide	DM02AWV	Advanced cancer	2A00-2F9Z	Approved	[71]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[72]
Epinephrine	DM3KJBC	Acute asthma	CA23	Approved	[73]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[74]
Fructose	DM43AN2	Vomiting	MD90	Approved	[75]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[76]
Glimepiride	DM5FSJA	Diabetic complication	5A2Y	Approved	[77]
Clonidine	DM6RZ9Q	Attention deficit hyperactivity disorder	6A05.Z	Approved	[78]
Propranolol	DM79NTF	Angina pectoris	BA40	Approved	[79]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[80]

Drug(s) Affected By ATP-binding cassette sub-family C member 4 (ABCC4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[81]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[82]
Zidovudine	DM4KI7O	Human immunodeficiency virus infection	1C62	Approved	[83]
Glutathione	DMAHMT9	Human immunodeficiency virus infection	1C62	Approved	[84]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[85]
Nefazodone	DM4ZS8M	Major depressive disorder	6A70.3	Approved	[86]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[87]
Aspirin	DM672AH	Acute coronary syndrome	BA41	Approved	[88]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[89]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[90]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Potassium channel unspecific (KC)	TT1VOHK	NOUNIPROTAC	Modulator	[2]

Drug Transporter (DTP)

DTP Name	DTP ID	UniProt ID	MOA	REF
Monocarboxylate transporter 6 (SLC16A5)	DT3I124	MOT6_HUMAN	Substrate	[3]
Organic anion transporting polypeptide 1B1 (SLCO1B1)	DT3D8F0	SO1B1_HUMAN	Substrate	[4]
Organic anion transporting polypeptide 1B3 (SLCO1B3)	DT9C1TS	SO1B3_HUMAN	Substrate	[5]

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 3A4 (CYP3A4)	DE4LYSA	CP3A4_HUMAN	Substrate	[6]
Cytochrome P450 2D6 (CYP2D6)	DECB0K3	CP2D6_HUMAN	Substrate	[7]
Cytochrome P450 2C9 (CYP2C9) Main DME	DE5IED8	CP2C9_HUMAN	Substrate	[6]
Cytochrome P450 3A5 (CYP3A5)	DEIBDNY	CP3A5_HUMAN	Substrate	[8]
Cytochrome P450 3A7 (CYP3A7)	DERD86B	CP3A7_HUMAN	Substrate	[8]
Prostaglandin G/H synthase 1 (COX-1)	DE073H6	PGH1_HUMAN	Substrate	[9]
UDP-glucuronosyltransferase 1A9 (UGT1A9)	DE85D2P	UD19_HUMAN	Substrate	[9]

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
ATP-binding cassette sub-family C member 4 (ABCC4)	OTO27PAL	MRP4_HUMAN	Drug Response	[10]
Insulin (INS)	OTZ85PDU	INS_HUMAN	Protein Interaction/Cellular Processes	[11]

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6833).
• [2] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [3] Quercetin, Morin, Luteolin, and Phloretin Are Dietary Flavonoid Inhibitors of Monocarboxylate Transporter 6. Mol Pharm. 2017 Sep 5;14(9):2930-2936.
• [4] Organic Anion Transporter 2-Mediated Hepatic Uptake Contributes to the Clearance of High-Permeability-Low-Molecular-Weight Acid and Zwitterion Drugs: Evaluation Using 25 Drugs. J Pharmacol Exp Ther. 2018 Nov;367(2):322-334.
• [5] FDA Drug Development and Drug Interactions
• [6] Drug-drug and food-drug pharmacokinetic interactions with new insulinotropic agents repaglinide and nateglinide. Clin Pharmacokinet. 2007;46(2):93-108.
• [7] Influence of CYP2C9 and CYP2D6 polymorphisms on the pharmacokinetics of nateglinide in genotyped healthy volunteers. Clin Pharmacokinet. 2004;43(4):267-78.
• [8] Drug Interactions Flockhart Table
• [9] Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
• [10] Multichannel liquid chromatography-tandem mass spectrometry cocktail method for comprehensive substrate characterization of multidrug resistance-associated protein 4 transporter. Pharm Res. 2007 Dec;24(12):2281-96.
• [11] Purification by p-aminobenzoic acid (PABA)-affinity chromatography and the functional reconstitution of the nateglinide/H+ cotransport system in the rat intestinal brush-border membrane. Biochem Biophys Res Commun. 2006 Feb 17;340(3):879-86. doi: 10.1016/j.bbrc.2005.12.092. Epub 2005 Dec 27.
• [12] Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357.
• [13] 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.
• [14] Mullard A: 2010 FDA drug approvals. Nat Rev Drug Discov. 2011 Feb;10(2):82-5.
• [15] Azimilide. Drugs. 2000 Feb;59(2):271-7; discussion 278-9.
• [16] Preclinical Mouse Models To Study Human OATP1B1- and OATP1B3-Mediated Drug-Drug Interactions in Vivo. Mol Pharm. 2015 Dec 7;12(12):4259-69.
• [17] Organic anion transporting polypeptide 1B1: a genetically polymorphic transporter of major importance for hepatic drug uptake. Pharmacol Rev. 2011 Mar;63(1):157-81.
• [18] Contribution of OATP1B1 and OATP1B3 to the disposition of sorafenib and sorafenib-glucuronide. Clin Cancer Res. 2013 Mar 15;19(6):1458-66.
• [19] Identification of drugs and drug metabolites as substrates of multidrug resistance protein 2 (MRP2) using triple-transfected MDCK-OATP1B1-UGT1A1-MRP2 cells. Br J Pharmacol. 2012 Mar;165(6):1836-1847.
• [20] The effect of SLCO1B1*15 on the disposition of pravastatin and pitavastatin is substrate dependent: the contribution of transporting activity changes by SLCO1B1*15. Pharmacogenet Genomics. 2008 May;18(5):424-33.
• [21] Influence of SLCO1B1, 1B3, 2B1 and ABCC2 genetic polymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipients. Eur J Clin Pharmacol. 2007 Dec;63(12):1161-9.
• [22] Rifampicin alters atorvastatin plasma concentration on the basis of SLCO1B1 521T>C polymorphism. Clin Chim Acta. 2009 Jul;405(1-2):49-52.
• [23] LST-2, a human liver-specific organic anion transporter, determines methotrexate sensitivity in gastrointestinal cancers. Gastroenterology. 2001 Jun;120(7):1689-99.
• [24] Effect of pregnane X receptor ligands on transport mediated by human OATP1B1 and OATP1B3. Eur J Pharmacol. 2008 Apr 14;584(1):57-65.
• [25] Influence of non-steroidal anti-inflammatory drugs on organic anion transporting polypeptide (OATP) 1B1- and OATP1B3-mediated drug transport. Drug Metab Dispos. 2011 Jun;39(6):1047-53.
• [26] Relevance of conserved lysine and arginine residues in transmembrane helices for the transport activity of organic anion transporting polypeptide 1B3. Br J Pharmacol. 2010 Feb 1;159(3):698-708.
• [27] Impact of OATP transporters on pharmacokinetics. Br J Pharmacol. 2009 Oct;158(3):693-705.
• [28] Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer. 2007 Mar 1;109(5):957-65.
• [29] Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica. 1998 Jun;28(6):539-47.
• [30] Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75.
• [31] Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metab Dispos. 2013 Feb;41(2):263-9.
• [32] Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
• [33] Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol. 2012 Apr;165(8):2787-98.
• [34] Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
• [35] The metabolism of zidovudine by human liver microsomes in vitro: formation of 3'-amino-3'-deoxythymidine. Biochem Pharmacol. 1994 Jul 19;48(2):267-76.
• [36] Inhibitory effects of anticancer drugs on dextromethorphan-O-demethylase activity in human liver microsomes. Cancer Chemother Pharmacol. 1993;32(6):491-5.
• [37] Effect of genetic polymorphism on the metabolism of endogenous neuroactive substances, progesterone and p-tyramine, catalyzed by CYP2D6. Brain Res Mol Brain Res. 2004 Oct 22;129(1-2):117-23.
• [38] CYP2D6 polymorphisms and tamoxifen metabolism: clinical relevance. Curr Oncol Rep. 2010 Jan;12(1):7-15.
• [39] Inhibition of cytochrome P450 2D6: structure-activity studies using a series of quinidine and quinine analogues. Chem Res Toxicol. 2003 Apr;16(4):450-9.
• [40] Effects of propofol on human hepatic microsomal cytochrome P450 activities. Xenobiotica. 1998 Sep;28(9):845-53.
• [41] Pharmacogenetics of schizophrenia. Am J Med Genet. 2000 Spring;97(1):98-106.
• [42] Roles of CYP2A6 and CYP2B6 in nicotine C-oxidation by human liver microsomes. Arch Toxicol. 1999 Mar;73(2):65-70.
• [43] Structure-activity relationship for human cytochrome P450 substrates and inhibitors. Drug Metab Rev. 2002 Feb-May;34(1-2):69-82.
• [44] Drug related genetic polymorphisms affecting adverse reactions to methotrexate, vinblastine, doxorubicin and cisplatin in patients with urothelial cancer. J Urol. 2008 Dec;180(6):2389-95.
• [45] Human prostate CYP3A5: identification of a unique 5'-untranslated sequence and characterization of purified recombinant protein. Biochem Biophys Res Commun. 1999 Jul 14;260(3):676-81.
• [46] Polymorphisms in cytochrome P4503A5 (CYP3A5) may be associated with race and tumor characteristics, but not metabolism and side effects of tamoxifen in breast cancer patients. Cancer Lett. 2005 Jan 10;217(1):61-72.
• [47] Induction of hepatic CYP2E1 by a subtoxic dose of acetaminophen in rats: increase in dichloromethane metabolism and carboxyhemoglobin elevation. Drug Metab Dispos. 2007 Oct;35(10):1754-8.
• [48] Urinary 6 beta-hydroxycortisol excretion in rheumatoid arthritis. Br J Rheumatol. 1997 Jan;36(1):54-8.
• [49] Clinical pharmacokinetics of imatinib. Clin Pharmacokinet. 2005;44(9):879-94.
• [50] Kinetics and regulation of cytochrome P450-mediated etoposide metabolism. Drug Metab Dispos. 2004 Sep;32(9):993-1000.
• [51] Differential mechanism-based inhibition of CYP3A4 and CYP3A5 by verapamil. Drug Metab Dispos. 2005 May;33(5):664-71.
• [52] The role of cytochrome P450 3A (CYP3A) isoform(s) in oxidative metabolism of testosterone and benzphetamine in human adult and fetal liver. J Steroid Biochem Mol Biol. 1993 Jan;44(1):61-7.
• [53] Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
• [54] Prediction of cytochrome P450 3A inhibition by verapamil enantiomers and their metabolites. Drug Metab Dispos. 2004 Feb;32(2):259-66.
• [55] The role of human cytochrome P450 enzymes in the formation of 2-hydroxymetronidazole: CYP2A6 is the high affinity (low Km) catalyst. Drug Metab Dispos. 2013 Sep;41(9):1686-94.
• [56] Progesterone and testosterone hydroxylation by cytochromes P450 2C19, 2C9, and 3A4 in human liver microsomes. Arch Biochem Biophys. 1997 Oct 1;346(1):161-9.
• [57] Tamoxifen inhibits cytochrome P450 2C9 activity in breast cancer patients. J Chemother. 2006 Aug;18(4):421-4.
• [58] Characterization of the oxidative metabolites of 17beta-estradiol and estrone formed by 15 selectively expressed human cytochrome p450 isoforms. Endocrinology. 2003 Aug;144(8):3382-98.
• [59] Drug-drug interactions with imatinib: an observational study. Medicine (Baltimore). 2016 Oct;95(40):e5076.
• [60] Drug interactions with calcium channel blockers: possible involvement of metabolite-intermediate complexation with CYP3A. Drug Metab Dispos. 2000 Feb;28(2):125-30.
• [61] New insights into the structural features and functional relevance of human cytochrome P450 2C9. Part I. Curr Drug Metab. 2009 Dec;10(10):1075-126.
• [62] A potential role for the estrogen-metabolizing cytochrome P450 enzymes in human breast carcinogenesis. Breast Cancer Res Treat. 2003 Dec;82(3):191-7.
• [63] A mechanistic approach to antiepileptic drug interactions. Ann Pharmacother. 1998 May;32(5):554-63.
• [64] Polymorphic expression of UGT1A9 is associated with variable acetaminophen glucuronidation in neonates: a population pharmacokinetic and pharmacogenetic study. Clin Pharmacokinet. 2018 Oct;57(10):1325-1336.
• [65] Glucuronidation of nonsteroidal anti-inflammatory drugs: identifying the enzymes responsible in human liver microsomes. Drug Metab Dispos. 2005 Jul;33(7):1027-35.
• [66] Pharmacokinetic interaction involving sorafenib and the calcium-channel blocker felodipine in a patient with hepatocellular carcinoma. Invest New Drugs. 2011 Dec;29(6):1511-4.
• [67] The evolution of population pharmacokinetic models to describe the enterohepatic recycling of mycophenolic acid in solid organ transplantation and autoimmune disease. Clin Pharmacokinet. 2011 Jan;50(1):1-24.
• [68] The UDP-glucuronosyltransferase 1A9 enzyme is a peroxisome proliferator-activated receptor alpha and gamma target gene. J Biol Chem. 2003 Apr 18;278(16):13975-83.
• [69] S-Naproxen and desmethylnaproxen glucuronidation by human liver microsomes and recombinant human UDP-glucuronosyltransferases (UGT): role of UGT2B7 in the elimination of naproxen. Br J Clin Pharmacol. 2005 Oct;60(4):423-33.
• [70] Peroxidative free radical formation and O-demethylation of etoposide(VP-16) and teniposide(VM-26). Biochem Biophys Res Commun. 1986 Feb 26;135(1):215-20.
• [71] Amino acid polymorphisms in the ATP-regulatable inward rectifier Kir6.2 and their relationships to glucose- and tolbutamide-induced insulin secretion, the insulin sensitivity index, and NIDDM. Diabetes. 1997 Mar;46(3):508-12. doi: 10.2337/diab.46.3.508.
• [72] The contribution of methotrexate exposure and host factors on transcriptional variance in human liver. Toxicol Sci. 2007 Jun;97(2):582-94.
• [73] A receptor mechanism for the inhibition of insulin release by epinephrine in man. J Clin Invest. 1967 Jan;46(1):86-94. doi: 10.1172/JCI105514.
• [74] Vasodilatory effects of troglitazone improve blood pressure at rest and during mental stress in type 2 diabetes mellitus. Hypertension. 1999 Jul;34(1):83-8. doi: 10.1161/01.hyp.34.1.83.
• [75] Quinapril treatment restores the vasodilator action of insulin in fructose-hypertensive rats. Clin Exp Pharmacol Physiol. 2002 May-Jun;29(5-6):381-5. doi: 10.1046/j.1440-1681.2002.03668.x.
• [76] Retinoic acid can induce markers of endocrine transdifferentiation in pancreatic ductal adenocarcinoma: preliminary observations from an in vitro cell line model. J Clin Pathol. 2006 Jun;59(6):603-10. doi: 10.1136/jcp.2005.032003. Epub 2006 Feb 10.
• [77] Effects of prolonged in vitro exposure to sulphonylureas on the function and survival of human islets. J Diabetes Complications. 2005 Jan-Feb;19(1):60-4. doi: 10.1016/j.jdiacomp.2004.05.001.
• [78] Clonidine effect on insulin secretion and lipolysis in man. Acta Diabetol Lat. 1978 May-Aug;15(3-4):192-7. doi: 10.1007/BF02581064.
• [79] Beta-adrenergic contribution to glucagon-induced glucose production and insulin secretion in uremia. Am J Physiol. 1986 Sep;251(3 Pt 1):E322-7. doi: 10.1152/ajpendo.1986.251.3.E322.
• [80] Effect of testosterone replacement on whole body glucose utilisation and other cardiovascular risk factors in males with idiopathic hypogonadotrophic hypogonadism. Horm Metab Res. 1998 Oct;30(10):642-5. doi: 10.1055/s-2007-978950.
• [81] Methotrexate normalizes up-regulated folate pathway genes in rheumatoid arthritis. Arthritis Rheum. 2013 Nov;65(11):2791-802.
• [82] Activation of beta-catenin signalling by GSK-3 inhibition increases p-glycoprotein expression in brain endothelial cells. J Neurochem. 2008 Aug;106(4):1855-65. doi: 10.1111/j.1471-4159.2008.05537.x. Epub 2008 Jul 4.
• [83] ATP binding cassette multidrug transporters limit the anti-HIV activity of zidovudine and indinavir in infected human macrophages. Antivir Ther. 2004 Aug;9(4):519-28.
• [84] Selenium-dependent and -independent transport of arsenic by the human multidrug resistance protein 2 (MRP2/ABCC2): implications for the mutual detoxification of arsenic and selenium. Carcinogenesis. 2010 Aug;31(8):1450-5. doi: 10.1093/carcin/bgq125. Epub 2010 Jun 27.
• [85] Development of a neural teratogenicity test based on human embryonic stem cells: response to retinoic acid exposure. Toxicol Sci. 2011 Dec;124(2):370-7.
• [86] Robustness testing and optimization of an adverse outcome pathway on cholestatic liver injury. Arch Toxicol. 2020 Apr;94(4):1151-1172. doi: 10.1007/s00204-020-02691-9. Epub 2020 Mar 10.
• [87] Hematopoietic stem cell differentiation affects expression and function of MRP4 (ABCC4), a transport protein for signaling molecules and drugs. Int J Cancer. 2009 May 15;124(10):2303-11. doi: 10.1002/ijc.24207.
• [88] Prolonged use of aspirin alters human and rat intestinal cells and thereby limits the absorption of clopidogrel. Clin Pharmacol Ther. 2011 Oct;90(4):612-9. doi: 10.1038/clpt.2011.163. Epub 2011 Sep 7.
• [89] Comparison of HepG2 and HepaRG by whole-genome gene expression analysis for the purpose of chemical hazard identification. Toxicol Sci. 2010 May;115(1):66-79.
• [90] Stem cell transcriptome responses and corresponding biomarkers that indicate the transition from adaptive responses to cytotoxicity. Chem Res Toxicol. 2017 Apr 17;30(4):905-922.